SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-154245
Filing Date
2023-05-25
Accepted
2023-05-25 16:23:09
Documents
13
Period of Report
2023-05-24
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K d367319d8k.htm   iXBRL 8-K 35956
  Complete submission text file 0001193125-23-154245.txt   194091

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA qncx-20230524.xsd EX-101.SCH 3881
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE qncx-20230524_def.xml EX-101.DEF 13697
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE qncx-20230524_lab.xml EX-101.LAB 22683
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE qncx-20230524_pre.xml EX-101.PRE 14665
7 EXTRACTED XBRL INSTANCE DOCUMENT d367319d8k_htm.xml XML 5155
Mailing Address 601 GATEWAY BOULEVARD, SUITE 1250 SOUTH SAN FRANCISCO CA 94080
Business Address 601 GATEWAY BOULEVARD, SUITE 1250 SOUTH SAN FRANCISCO CA 94080 415-910-5717
Quince Therapeutics, Inc. (Filer) CIK: 0001662774 (see all company filings)

IRS No.: 901024039 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38890 | Film No.: 23960968
SIC: 2836 Biological Products, (No Diagnostic Substances)